

1 **Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV**
2 **viraemia and drug resistance among people receiving dolutegravir and efavirenz-based**
3 **antiretroviral therapy**

4
5 **Authors:** Jienchi Dorward^{1,2}, Richard Lessells^{2,3}, Katya Govender⁴, Pravikrishnen Moodley⁵,
6 Natasha Samsunder², Yukteshwar Sookrajh⁶, Phil Turner¹, Christopher C Butler¹, Gail
7 Hayward¹, Monica Gandhi⁷, Paul K. Drain^{8,9,10}, Nigel Garrett^{2,11}

8
9 **Affiliations:**

- 10 1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
11 2. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of
12 KwaZulu-Natal, Durban, South Africa.
13 3. KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of
14 KwaZulu-Natal, Durban, South Africa
15 4. Africa Health Research Institute, Durban, South Africa
16 5. Department of Virology, University of KwaZulu-Natal and National Health Laboratory
17 Service, Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa
18 6. eThekweni Municipality Health Unit, Durban, South Africa
19 7. Division of HIV, Infectious Disease, and Global Medicine, Department of Medicine,
20 University of California, San Francisco (UCSF), San Francisco, CA
21 8. Department of Global Health, Schools of Medicine and Public Health, University of
22 Washington, Seattle, USA.
23 9. Department of Medicine, School of Medicine, University of Washington, Seattle, USA.
24 10. Department of Epidemiology, School of Public Health, University of Washington, Seattle,
25 USA.
26 11. Discipline of Public Health Medicine, School of Nursing and Public Health, University of
27 KwaZulu-Natal, Durban, South Africa

28
29 **Corresponding Author:**

30 Jienchi Dorward
31 Nuffield Department of Primary Care Health Sciences, University of Oxford,
32 Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2
33 6GG; Email: jienchi.dorward@phc.ox.ac.uk

34

35 **Word count: 3461/3500**

36

37 **Keywords:** HIV, point-of-care, tenofovir, adherence, viral failure

38

39

40 **ABSTRACT (287)**

41 **Introduction:** Novel point-of-care assays which measure urine tenofovir (TFV) concentrations
42 may have a role in improving adherence monitoring for people living with HIV (PLHIV) receiving
43 antiretroviral therapy (ART). However, further studies of their diagnostic accuracy, and whether
44 results are associated with viraemia and drug resistance, are needed to guide their use,
45 particularly in the context of the global dolutegravir rollout.

46 **Methods:** We conducted a cross-sectional evaluation among PLHIV receiving first-line ART
47 containing tenofovir disoproxil fumarate (TDF). We calculated the diagnostic accuracy of the
48 Abbott point-of-care assay to detect urine TFV measured by liquid chromatography and mass
49 spectrometry. We evaluated the association between point-of-care urine TFV results and self-
50 reported adherence, viraemia ≥ 1000 copies/mL, and HIV drug resistance, among people
51 receiving either efavirenz or dolutegravir-based ART.

52 **Results:** Among 124 participants, 55% were women, median age was 39 (IQR 34-45) years. 74
53 (59.7%) were receiving efavirenz, and 50 (40.3%) dolutegravir. Sensitivity and specificity to
54 detect urine TFV ≥ 1500 ng/mL were 96.1% (95%CI 90.0-98.8) and 95.2% (75.3-100.0)
55 respectively. Urine TFV results were associated with short ($p < 0.001$) and medium term
56 ($p = 0.036$) self-reported adherence. Overall, 44/124 (35.5%) had viraemia, which was
57 associated with undetectable TFV in those receiving efavirenz (OR 6.01, 1.27-39.0, $p = 0.014$)
58 and dolutegravir (OR 25.7, 4.20-294.8, $p < 0.001$). However, in those with viraemia while
59 receiving efavirenz, 8/27 (29.6%) had undetectable urine TFV, compared to 11/17 (64.7%) of
60 those receiving dolutegravir. Drug resistance was detected in 23/27 (85.2%) of those receiving
61 efavirenz and only 1/16 (6.3%) of those receiving dolutegravir. There was no association
62 between urine TFV results and drug resistance.

63 **Conclusions:** Among PLHIV receiving ART, a rapid urine TFV assay can be used to
64 accurately monitor urine TFV levels. Undetectable point-of-care urine TFV results were
65 associated with viraemia, particularly among people receiving dolutegravir.

66 **Trial registration:** Pan-African Clinical Trials Registry: PACTR202001785886049.

67

68 INTRODUCTION

69 Early identification and management of HIV viraemia among people living with HIV (PLHIV)
70 receiving antiretroviral treatment (ART) is important to ensure rapid viral re-suppression, which
71 in turn prevents HIV transmission, the development of HIV drug resistance (HIVDR), and
72 morbidity and mortality [1]. Viraemia may be caused by inconsistent adherence to effective ART
73 and/or HIVDR, but in low- and middle-income countries (LMICs), resistance and drug level
74 testing are not widely available [2], making management of viraemia more difficult for clinicians.

75 Tenofovir disoproxil fumarate (TDF) is a key component of World Health Organization
76 recommended ART and is used by over 95% of people receiving ART in LMICs [3, 4], thereby
77 serving as a potential target for objective adherence monitoring. TDF is metabolised to tenofovir
78 (TFV), which is converted intracellularly to TFV-diphosphate (TFV-DP). TFV has a short plasma
79 half-life [5] and is excreted renally, meaning it is readily measured in urine. TFV-DP
80 accumulates in red blood cells (RBCs) and peripheral blood mononuclear cells and has a longer
81 half-life[6] than plasma TFV. Urine TFV concentrations have mainly been evaluated among
82 people without HIV, who are using TDF as part of pre-exposure prophylaxis [7], showing an
83 association with HIV seroconversion [8, 9]. However, measurement can require liquid
84 chromatography tandem mass spectrometry (LC-MS/MS), which is not feasible in many
85 settings. More recently, point-of-care urine TFV assays using antibody-based technology have
86 been developed which can be readily used in clinical settings to accurately detect TDF
87 adherence within the past 2-5 days [10].

88 While several clinical trials are planned or underway to evaluate the clinical impact of point-of-
89 care urine TFV assays on HIV treatment outcomes[11, 12, 13], more observational data is
90 needed to further evaluate diagnostic accuracy, and associations between point-of-care urine
91 TFV results with HIV viraemia and drug resistance. In the context of the global rollout of the
92 fixed-dose combination of tenofovir-lamivudine-dolutegravir (TLD), objective measures of
93 adherence may be even more useful. Dolutegravir is an integrase inhibitor (INSTI) with a high
94 genetic barrier to resistance and emergent drug resistance has so far been rare [14], meaning
95 viraemia is most likely secondary to non-adherence. In contrast, previously recommended non-
96 nucleoside reverse transcriptase inhibitors (such as efavirenz) are more susceptible to the
97 development of drug resistance, meaning viraemia may be caused by either poor adherence or
98 drug resistance. Thereby, demonstrating good adherence in the presence of viraemia on
99 efavirenz based ART may help identify people with drug resistance.

100 In this study, we aimed to evaluate the diagnostic accuracy of a point-of-care test to detect urine
101 TFV, compared to the reference standard LC-MS/MS. We also aimed to describe the
102 association between point-of-care urine TFV results, and HIV viraemia, drug resistance, and
103 self-reported adherence, among people receiving dolutegravir versus efavirenz. We
104 hypothesized that a detectable urine TFV result on the point-of-care test would be more strongly
105 associated with viral suppression among people receiving dolutegravir compared to efavirenz,
106 because of the lower likelihood of drug resistance with dolutegravir. We also hypothesised that
107 in people with confirmed viraemia, a detectable urine TFV result would be associated with HIV
108 drug resistance among people receiving efavirenz.

109 **METHODS**

110 **Study design**

111 We conducted a prospective diagnostic accuracy sub-study within the POWER study. POWER is
112 an open-label, individually randomised, feasibility study of point-of-care HIV viral load (VL)
113 testing to enhance re-suppression among people with HIV viraemia while receiving first-line
114 ART. The POWER protocol has been previously published[15].

115 **Participants**

116 We included all consecutive participants enrolled into POWER who were taking tenofovir
117 disoproxil fumarate. PLHIV were eligible for enrolment into POWER if they were receiving first-
118 line dolutegravir or efavirenz-based ART and with recent viraemia >1000 copies/mL in the past
119 6 weeks, for which they had not yet received enhanced adherence counselling. At enrolment,
120 participants provided sociodemographic and clinical details, including self-reported adherence,
121 and had urine, dried blood spot and plasma samples taken and stored at -80°C, for
122 retrospective testing.

123 **Test Methods**

124 *Point-of-care urine TFV testing*

125 We thawed the frozen urine samples and tested them according to manufacturer's instructions
126 using the Abbott (Abbott, Chicago, USA) lateral flow point-of-care urine TFV assay. Specifically,
127 3-4 drops of urine were added to the test well, and the result was read by two independent
128 laboratory technicians after 3-5 minutes. Photos of discrepant results were adjudicated by a
129 third investigator.

130 *Reference standard urine TFV, and TFV-DP concentrations*

131 We used LC-MS/MS at the Africa Health Research Institute in Durban to quantitate TFV levels
132 in thawed urine samples, and measure TFV-DP concentrations in dried blood spots (DBS) (see
133 supplementary material for details).

134 *Viral load and HIVDR*

135 We tested VL with the cobas[®] HIV-1 assay using the cobas 6800 platform (Roche, Basel,
136 Switzerland) in the National Health Laboratory Service at the Inkosi Albert Luthuli Hospital in
137 Durban. We attempted sequencing of HIV-1 *pol* (protease [PR], reverse transcriptase [RT] and
138 integrase [IN]) for all samples with VL ≥ 1000 copies/mL. Following RNA extraction, we amplified
139 PR, RT and IN genes using the amplification module of the Applied Biosystems HIV-1
140 Genotyping Kit with Integrase (Thermo Fisher Scientific, Waltham, MA); and sequenced on the
141 Illumina MiSeq platform (Illumina, San Diego, CA). We identified drug resistance mutations
142 (DRMs) at $>20\%$ frequency using Stanford HIVdb (version 9.1).

143 For all the above testing methods, the person conducting the test was blinded to the results
144 from other methods.

145 **Statistical analysis**

146 We assessed the diagnostic accuracy (sensitivity, specificity and positive and negative
147 predictive values), of the point-of-care TFV test to detect urine TFV at the manufacturer stated
148 threshold of 1500ng/mL. We compared self-reported short-term and longer-term adherence with
149 point-of-care urine TFV results using logistic regression models. We then described the
150 proportions of PLHIV with and without viraemia ≥ 1000 copies/mL who had detectable and
151 undetectable point-of-care urine TFV tests. To determine the usefulness of the urine TFV test to
152 predict viraemia and suppression in this study population, we calculated the pre-test probability
153 (prevalence of viraemia and suppression before testing), and the post-test probability
154 (prevalence after stratification by urine TFV test result). Among participants with a VL ≥ 1000
155 copies/mL, we also assessed proportions with and without HIV drug resistance who had
156 detectable and undetectable point-of-care urine TFV results, and pre- and post-test probabilities
157 for drug resistance. We conducted the above analyses separately among participants receiving
158 efavirenz or dolutegravir. We also conducted sensitivity analyses using a viraemic threshold of
159 ≥ 50 copies/mL. Lastly, among people with unexpected urine TFV results based on viraemia and
160 HIV drug resistance results (e.g. viraemia, no HIV drug resistance, but *detectable* point-of-care
161 urine TFV), we assessed longer term adherence by describing TFV-DP levels in DBS[6, 16].

162 Sample size was determined by the number of participants enrolled into POWER and receiving
163 TDF. We analysed data using R 4.2.0 (R Foundation for Statistical Computing, Vienna, Austria).

164 **Ethical approvals**

165 The eThekweni Municipality Health Unit Research Committee, the KwaZulu-Natal Provincial
166 Health Research Ethics Committee (KZ_202002_005), the University of KwaZulu-Natal
167 Biomedical Research Ethics Committee (BREC 00000836/2019) and the University of Oxford
168 Tropical Research Ethics Committee (OxTREC 66-19) approved the study. POWER is
169 registered on the Pan African Clinical Trials Registry (PACTR202001785886049) and the South
170 African Clinical Trials Registry (DOH-27-072020-6890).

171 **RESULTS**

172 **Study population**

173 Between August 20th, 2020 and March 25th, 2022, we enrolled 125 participants into POWER
174 (Figure 1), of whom 124 were receiving TDF and were included in this analysis. The median age
175 was 39 years (interquartile range [IQR] 34-45) and 68 (54.8%) were women (Table 1). A total of
176 74 (59.7%) were receiving efavirenz for a median of 4.2 years (2.1 to 6.0), and 50 (40.3%) were
177 receiving dolutegravir, for a median of 0.6 years (0.5-1.0). Median time since the pre-enrolment
178 viraemic VL was 15 days (13-21). In December 2020, we were informed that 45 participants had
179 their pre-enrolment VLs measured on a defective VL analyser which had been overestimating
180 some VL results. Therefore, the viraemic sample used to determine eligibility may have been
181 falsely high. After discussion with the ethics committees, we continued to include these
182 participants in POWER and in this sub-study in order to have a wide range of VL results. At
183 enrolment, 57/124 (46.0%) were virally suppressed <50 copies/mL, 23/124 (18.5%) had VL 50-
184 999 copies/mL, and 44/124 participants (35.5%) had viraemia \geq 1000 copies/mL. Among the 43
185 with successful HIVDR testing 24/43 (55.8%) had mutations conferring resistance to their
186 current regimen. Among those receiving efavirenz, 23/27 (85.2%) had resistance to their current
187 regimen, versus 1/16 (6.3%) of those receiving dolutegravir (one person with M184V mutation
188 alone). Overall, 23.4% self-reported missing a dose in the past 4 days, and 62.9% reported last
189 missing a dose over four weeks ago (**Error! Reference source not found.**).

190 **Point-of-care urine TFV test**

191 *Diagnostic accuracy*

192 At enrolment, 100 (80.6%) had urine TFV detected with the point-of-care test. Median LCMS-
193 MS urine TFV concentration was 20000 ng/mL (7280-33625). Compared to quantitative urine
194 TFV concentrations, the point-of-care TFV test was accurate at detecting TFV at the
195 manufacturer stated threshold of 1500 ng/mL, with a sensitivity of 96.1% (95% confidence
196 interval [CI] 90.0-98.8), and specificity of 95.2% (75.3-100.0, Table 2). All five discrepant results
197 occurred in samples with LCMS-MS TFV between 500 and 3000ng/mL (Table S1).

198 *Self-reported adherence*

199 Among all participants, self-reported missed doses in the past four days and more recently self-
200 reported missed doses were both associated with undetectable point-of-care urine TFV (Table
201 S2). However, 12/95 (12.6%) people who reported missing no doses in the past four days had
202 undetectable urine tenofovir. Two of these were false negatives, with LC-MS/MS concentrations
203 >1500 ng/mL, and so were incorrectly classified as 'non-adherent' by the point-of-care test.

204 *Association with viraemia*

205 Undetectable TFV on point-of-care urine testing was associated with viraemia ≥ 1000 copies/mL
206 in people receiving efavirenz (odds ratio [OR] 6.01, 1.27-39.0, $p=0.014$) and dolutegravir (OR
207 25.7, 4.20-294.8, $p<0.001$). Among those with viraemia ≥ 1000 copies/mL, 29.6% (13.8-50.2) of
208 those receiving EFV had undetectable TFV, compared to 64.7% (41.1-82.7) of those receiving
209 DTG (Fisher's exact test for difference $p=0.031$, Table 3). Among those with viral suppression
210 < 1000 copies/mL, 93.6% (82.0-98.4) of those receiving EFV and 93.9% (79.2-99.2) of those
211 receiving DTG had a detectable urine TFV.

212 Among all people receiving efavirenz, the pre-test probability was 36.5% (26.5-47.9) for
213 viraemia and 63.5% (52.1-73.5) for viral suppression. After urine TFV testing, of those with
214 undetectable urine TFV, the post-test probability was 72.7% (42.8-90.5) for viraemia, and of
215 those with detectable urine TFV, 69.8% (57.5-79.8) for viral suppression (Table 3). Among
216 those receiving dolutegravir, the pre-test probability was 34.0% (22.4-47.9) for viraemia and
217 66.0% (52.1-77.6) for viral suppression. Of those with undetectable urine TFV, the post-test
218 probability was 84.6% (56.3-96.6) for viraemia, and of those with detectable urine TFV, 83.8%
219 (68.4-92.6) for viral suppression.

220 At a threshold of ≥ 50 copies/mL, undetectable point-of-care urine TFV results remained
221 associated with viraemia among those receiving efavirenz ($p = 0.018$) and those receiving
222 dolutegravir ($p = 0.002$, Table S3), with 100% of those with undetectable TFV having viraemia.

223 *Association with HIV drug resistance*

224 Among 43 people with viraemia and successful HIV drug resistance testing, detectable point-of-
225 care urine TFV results were not associated with HIV drug resistance against the current
226 regimen in those receiving efavirenz ($p = 1.000$) or dolutegravir ($p = 0.375$). Of those receiving
227 efavirenz, and with viraemia ≥ 1000 copies/ml, 23/27 (85.2%, 66.7-94.6) had drug resistance to
228 their current regimen, and of these 23, 16 had a detectable urine TFV (69.6%, 48.9-84.4, Table
229 2). Of those without HIVDR, 1/4 (25.0%, 4.0-71.0) had undetectable urine TFV. Among those
230 receiving dolutegravir, only 1/16 (6.3%, 0.0-30.6) had drug resistance to their current regimen
231 (M184V mutation). This one participant had a detectable urine TFV test, while 10/15 without
232 HIVDR (66.7%, 41.5-84.8) had undetectable urine TFV. When looking at only drug resistance
233 against nucleoside reverse transcriptase inhibitors (NRTIs), there was again no association with
234 urine TFV results among those receiving efavirenz ($p=0.658$) or dolutegravir ($p=0.375$).

235 Regarding the ability of the urine TFV test to predict HIVDR among people with viraemia,
236 among people receiving efavirenz, the pre-test probability of HIVDR was 85.2% (66.7-94.6), and
237 of not having HIVDR 14.8% (5.4-33.3). 19 people had detectable urine TFV, of whom 16 had
238 HIVDR (post-test probability of HIVDR 84.2%, 61.4-95.1). Eight had undetectable urine TFV,
239 and of these, only one did not have HIVDR (post-test probability of no HIVDR 12.5%, 0.5-49.5).
240 Among people with viraemia and receiving dolutegravir, the pre-test probability of HIVDR was
241 6.3% (0.0-30.6), and of not having HIVDR, 93.7%. Six had detectable urine TFV, of which only
242 one had HIVDR (post-test probability of HIVDR 16.7%, 1.6-58.4). Ten had undetectable TFV,
243 and of these none had drug resistance (post-test probability of no HIVDR 100%, 67.4-100.0).

244 *TFV-DP levels*

245 Among the eight participants with viraemia, no HIVDR, and *detectable* urine TFV, one
246 participant had LCMS urine TFV levels < 1500 ng/mL, suggesting a false positive, detectable
247 point-of-care urine TFV test. Of the remaining seven, urine TFV levels were > 1500 ng/mL,
248 suggesting recent TDF ingestion, but 6/7 had TFV-DP levels < 700 fmol/punch, which
249 corresponds to poor longer-term adherence with an estimated 0-3 tablets per week[6, 16] (Table
250 S4A). Among the five participants with viral load < 1000 copies/mL, but *undetectable* urine TFV,
251 two had LMCS urine TFV levels > 1500 ng/mL, suggesting false negative, undetectable point-of-

252 care urine TFV results. The remaining three participants had TFV-DP levels between 200 and
253 550 fmol/punch, again suggesting inconsistent longer-term adherence (Table S4B).

254 **DISCUSSION**

255 **Summary**

256 In this cross-sectional study in South Africa, we demonstrate that a novel point-of-care test is
257 accurate at detecting urine TFV, and identifies additional people with sub-optimal adherence
258 compared to self-reported adherence measures. Furthermore, undetectable point-of-care urine
259 TFV results were associated with viraemia, in particular among people receiving dolutegravir.
260 Among people with viraemia, point-of-care urine TFV results were not associated with HIV drug
261 resistance.

262 **Interpretation**

263 *Self-reported adherence*

264 We demonstrated an association between self-reported adherence and urine TFV levels, and
265 found that around 10% of people who reported missing no doses in the past four days had
266 undetectable urine tenofovir using the point-of-care test. Therefore, this test could help identify
267 people with unreported sub-optimal adherence.

268 *Viraemia*

269 Undetectable urine TFV results were associated with viraemia, in particular among people
270 receiving dolutegravir. Only 32% of those with viraemia while receiving efavirenz had an
271 undetectable urine TFV; the majority had detectable urine TFV. However, this discrepancy can
272 be explained by the high prevalence of HIV drug resistance among people receiving efavirenz,
273 meaning that drug resistance, rather than current poor adherence, was driving viraemia.
274 Conversely, among people receiving dolutegravir, 63% of those with viraemia had undetectable
275 urine TFV, suggesting that for these participants, poor adherence was the main cause of
276 viraemia. This is supported by the low prevalence of HIV drug resistance in participants on
277 dolutegravir. Furthermore, among those with viraemia and a detectable urine TFV, TFV-DP
278 results suggested poor longer term adherence. In our study, the post-test probability of viraemia
279 or suppression at a threshold of 1000 copies/mL was over 80% among those receiving
280 dolutegravir, suggesting that this test could be used to triage people receiving dolutegravir into
281 different clinical pathways. At a threshold of 50 copies/mL, an undetectable urine TFV very
282 strongly predicted viraemia, but a detectable urine TFV performed less well at confirming viral

283 suppression, likely because of the more sustained adherence required to suppress to <50
284 copies/mL.

285 *HIV Drug Resistance*

286 We did not find evidence of an association between urine TFV test results and HIV drug
287 resistance among people with viraemia (≥ 1000 copies/mL) receiving efavirenz or dolutegravir,
288 which may be partly explained by the small sample size, meaning that estimates were not
289 precise. However, the very high prevalence of HIVDR among people receiving efavirenz (high
290 pre-test probability of drug resistance), meant that the test did not ‘add value’, as the post-test
291 probability of drug resistance remained similarly high. Likewise, the very low prevalence of
292 resistance among people receiving dolutegravir (low pre-test probability), meant that the test
293 was again not helpful, with post-test probabilities remaining similar.

294 **Comparison with other studies**

295 There is one other published study assessing the analytic performance of the Abbot point-of-
296 care tenofovir assay, conducted as part of its development and validation. In 300 randomly
297 selected stored urine samples from the TARGET TDF dosing trial,[17] the point-of-care urine
298 tenofovir assay had sensitivity of 97% (95-99) and specificity of 99% (94-100) at a cut-off of
299 1500ng/mL.[10] This cut-off was selected as it would correctly classify 98% of people who took
300 a TDF dose 24 hours ago as adherent, and 86% of those who last took a dose 96 hours ago as
301 non-adherent.[18] Of note, all the discrepant results in our analysis were close to the cut-off of
302 1500ng/mL.

303 Our findings are similar to those in recent studies which have assessed various point-of-care
304 urine tenofovir assays, and their relationship with viraemia and/or HIVDR. A study from Lesotho
305 among PLHIV receiving TDF-based ART (95% on dolutegravir) found that the UrSure point-of-
306 care test (now known as SureQuick Rapid Tenofovir Adherence Test [OraSure Technologies
307 Inc., USA]) did not detect urine TFV in 1/8 (12.5%) with viraemia ≥ 1000 copies/mL, and
308 detected urine TFV in 395/398 (99%) of those with viral suppression [19]. Of the 8 with viraemia,
309 7 were receiving efavirenz-based ART, but HIVDR testing was not done.

310 A case control study within the ADVANCE clinical trial in South Africa matched 139 participants,
311 recently initiated on ART and with rebound viraemia, with 53 non-viraemic controls [20]. 66% of
312 participants with viraemia ≥ 200 copies/mL had an undetectable SureQuick Rapid Tenofovir
313 Adherence Test, and 100% of those with viral suppression had a detectable urine TFV, which is
314 similar to our findings. Among the 42 with successful drug resistance testing, drug resistance

315 was detected in 16.7% of those receiving dolutegravir, and 61.1% of those receiving efavirenz.
316 Overall, a detectable urine TFV result was associated with the presence of NRTI resistance
317 alone, but not with the presence of NRTI/NNRTI resistance. This may reflect the persistence of
318 NNRTI mutations in the absence of drug pressure, whereas NRTI mutations are more likely to
319 be superceded by wild type virus if ART is not being taken.

320 Another South African study, among 113 people with previous viraemia or treatment
321 interruptions, found that among people with viraemia ≥ 400 copies/mL, 64.7% of those receiving
322 dolutegravir/boosted protease inhibitors had an undetectable Abbott point-of-care urine TFV
323 result, compared to only 4.8% among those receiving efavirenz. Only one person receiving
324 efavirenz had undetectable urine TFV [21]. Similar to our findings, among those receiving
325 dolutegravir/boosted protease inhibitors, 85% of those with undetectable urine TFV had
326 viraemia, and 85% of those with detectable urine TFV were suppressed. As in our study, the
327 prevalence of HIVDR was high among people with efavirenz (18/20, 90%), and much lower
328 among those receiving dolutegravir (5/16 = 31%), although associations between HIVDR and
329 urine TFV results were not evaluated. Two other studies, focusing on people with viraemia while
330 receiving efavirenz, found associations between positive point-of-care urine TFV results and
331 HIVDR mutations, but similar to our findings, the prevalence of HIVDR mutations was high, and
332 so the pre- and post-test probabilities of HIVDR did not change much after a positive urine TFV
333 test[22, 23].

334 **Strengths and limitations**

335 This is one of the first evaluations of the analytic performance of the Abbot point-of-care urine
336 tenofovir assay, beyond the validation conducted as part of the assay's development.[10] We
337 were also able to use viral load and HIV drug resistance results to evaluate the clinical utility of
338 the assay, and our inclusion of people receiving dolutegravir is important given the ongoing
339 dolutegravir rollout. Limitations of our study include the use of frozen urine samples for
340 retrospective point-of-care testing by laboratory staff, the short period which participants had
341 been receiving dolutegravir, and the relatively small sample size, particularly of people with
342 viraemia and drug resistance, which resulted in wide confidence intervals. Our study design
343 meant that we enrolled people a median of 15 days after first viraemia, meaning that adherence
344 patterns could have changed, particularly if people had collected ART at the visit when blood
345 was taken for the first viraemic VL. This cross-sectional analysis also does not explore the
346 relationship between current adherence measures and future outcomes.

347 **Implications for research and policy**

348 Our findings provide further evidence to support the use of point-of-care urine TFV assays as
349 objective indicators of adherence, and provide further insights into where they may be best
350 employed in clinical practice. The moderate performance at predicting viraemia seen in our and
351 other studies suggests that current point-of-care urine TFV assays cannot replace VL testing,
352 but could be used in-between annual VL testing to monitor adherence, and to trigger VL testing
353 if poor adherence is suspected. This may be particularly useful in people with viraemia receiving
354 dolutegravir, or in differentiated ART delivery programmes in community settings. While our
355 findings suggest limited utility in identifying resistance among people with viraemia while the
356 prevalence of dolutegravir resistance is low, further work is needed to determine whether the
357 point-of-care urine TFV test could be useful as a triage test to guide HIV drug resistance testing
358 as the dolutegravir rollout matures.

359 **Conclusion**

360 Point-of-care urine TFV may be used to monitor ART adherence and predict viraemia,
361 particularly in people receiving dolutegravir.

362 **LIST OF ABBREVIATIONS**

363 ART – antiretroviral therapy
364 AUC – area under the curve
365 DBS – dried blood spot
366 HIVDR – HIV drug resistance
367 INSTI – integrase inhibitor
368 LMIC – low- and middle-income countries
369 NRTI – nucleotide reverse transcriptase inhibitor
370 NNRTI – non-nucleotide reverse transcriptase inhibitor
371 NPV – negative predictive value
372 PLHIV – people living with HIV
373 PPV – positive predictive value
374 ROC – receiver operating characteristic
375 TDF – tenofovir disoproxil fumarate
376 TFV – tenofovir
377 TFV-DP – tenofovir diphosphate
378 VL – viral load

379

380 **DECLARATIONS**

381 **Competing interests**

382 Abbott provided the urine TFV assays at no cost. The authors have no other competing
383 interests to declare.

384

385 **Funding**

386 This work is supported by grants from the Wellcome Trust PhD Programme for Primary Care
387 Clinicians (216421/Z/19/Z), the University of Oxford's Research England QR Global Challenges
388 Research Fund (0007365) and the Africa Oxford Initiative (AfiOx-119). HIV drug resistance
389 testing and drug concentration testing was funded by the National Institute for Health and Care
390 Research (NIHR) Community Healthcare MedTech and In Vitro Diagnostics Co-operative at
391 Oxford Health NHS Foundation Trust (MIC-2016-018); GH, CCB & PJT also receive funding
392 from this award. The views expressed are those of the author(s) and not necessarily those of
393 the NHS, the NIHR or the Department of Health and Social Care. For the purpose of open
394 access, the author has applied a CC BY public copyright licence to any Author Accepted
395 Manuscript version arising from this submission. The University of Oxford is the study sponsor.
396 The funders and sponsor had no role in study design, manuscript submission, or collection,
397 management, analysis or interpretation of study data.

398

399 **Author contributions**

400 JD, PKD and NG conceived the study. RL, KG, PM and NS were responsible for laboratory
401 testing. RL, YS, CB and GH contributed to study design. MG developed the urine TFV assay.
402 JD analysed the data and wrote the first draft of the manuscript. All authors critically reviewed
403 and edited the manuscript and consented to final publication.

404 **Acknowledgements**

405 The authors would like to thank all participants in the study and acknowledge the work and
406 support of staff at the Prince Cyril Zulu Clinic, Mafakathini Clinic, eThekweni Municipality,
407 CAPRISA, AHRI Pharmacology Core, KRISP and the National Health Laboratory Services at
408 Inkosi Albert Luthuli Hospital.

409

410 **Data sharing statement**

411 Bona fide researchers will be able to request access to anonymised trial data by contacting the
412 corresponding author.
413

414 REFERENCES

- 415 1. Murphy RA, Court R, Maartens G, Sunpath H. Second-line antiretroviral therapy in sub-
416 Saharan Africa: It's time to mind the gaps. *AIDS Research and Human Retroviruses*.
417 2017;33(12):1181-4.
- 418 2. Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and
419 middle-income countries. *The Lancet HIV*. 2018;5(10):e588-e96.
- 420 3. World Health Organization. Consolidated guidelines on HIV prevention, testing,
421 treatment, service delivery and monitoring: recommendations for a public health approach.
422 Geneva, Switzerland: World Health Organization; 2021.
- 423 4. Clinton Health Access Initiative. 2021 HIV Market Report: The state of the HIV market in
424 low- and middle-income countries. Boston, USA: Clinto Health Access Initiative.; 2021.
- 425 5. Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al.
426 Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments
427 from First Dose to Steady State. *AIDS Res Hum Retroviruses*. 2016;32(10-11):981-91.
- 428 6. Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, et al.
429 Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent
430 and cumulative drug exposure. *AIDS Res Hum Retroviruses*. 2013;29(2):384-90.
- 431 7. Drain PK, Bardon AR, Simoni JM, Cressey TR, Anderson P, Sevenler D, et al. Point-of-
432 care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and
433 Prevention. *Curr HIV/AIDS Rep*. 2020;17(5):487-98.
- 434 8. Spinelli MA, Glidden DV, Rodrigues WC, Wang G, Vincent M, Okochi H, et al. Low
435 tenofovir level in urine by a novel immunoassay is associated with seroconversion in a
436 preexposure prophylaxis demonstration project. *AIDS*. 2019;33(5):867-72.
- 437 9. Stalter RM, Baeten JM, Donnell D, Spinelli MA, Glidden DV, Rodrigues WC, et al. Urine
438 Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency
439 Virus Protection. *Clin Infect Dis*. 2021;72(3):486-9.
- 440 10. Gandhi M, Wang G, King R, Rodrigues WC, Vincent M, Glidden DV, et al. Development
441 and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment
442 and prevention in real-time in routine settings. *AIDS*. 2020;34(2):255-60.
- 443 11. Bardon AR, Dorward J, Sookrajh Y, Sayed F, Quame-Amaglo J, Pillay C, et al.
444 Simplifying TREATment and Monitoring for HIV (STREAM HIV): protocol for a randomised
445 controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes.
446 *BMJ Open*. 2021;11(10):e050116.
- 447 12. Gandhi M, Orrell C, Singh Y, Jennings L. Urine Tenofovir Point-of-care Test to Identify
448 Patients in Need of ART Adherence Support (UTRA Study) *ClinicalTrials.gov*:
449 *ClinicalTrials.gov*; 2022 [Available from: <https://clinicaltrials.gov/ct2/show/NCT05333679>.
- 450 13. McCluskey S. A Randomized Clinical Trial to Evaluate Solutions for the Management of
451 Virologic Failure on TLD in Sub-Saharan Africa (RESOLVE) *ClinicalTrials.gov*:
452 *ClinicalTrials.gov*; 2022 [Available from: <https://clinicaltrials.gov/ct2/show/NCT05373758>.
- 453 14. Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al.
454 Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus
455 efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection
456 (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV*.
457 2020;7(10):e666-e76.
- 458 15. Dorward J, Sookrajh Y, Ngobese H, Lessells R, Sayed F, Bulu E, et al. Protocol for a
459 randomised feasibility study of Point-Of-care HIV viral load testing to Enhance Re-suppression
460 in South Africa: the P^OWER study. *BMJ Open*. 2021;11(2):e045373.
- 461 16. Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, et al.
462 Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots
463 following Directly Observed Therapy. *Antimicrob Agents Chemother*. 2018;62(1).

- 464 17. Cressey TR, Siriprakaisil O, Klinbuayaem V, Quame-Amaglo J, Kubiak RW,
465 Sukrakanchana P-o, et al. A randomized clinical pharmacokinetic trial of Tenofovir in blood,
466 plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
467 BMC Infectious Diseases. 2017;17(1):496-.
- 468 18. Gandhi M, Bacchetti P, Spinelli MA, Okochi H, Baeten JM, Siriprakaisil O, et al. Brief
469 Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and
470 ART and Establishing the Cutoff for a Point-of-Care Test. J Acquir Immune Defic Syndr.
471 2019;81(1):72-7.
- 472 19. Marryshow TA, Muhairwe J, Tang A, Molulela MMM, Matta R, Jordan MR. Determining
473 the acceptability of point-of-care urine tenofovir testing and its performance in predicting HIV
474 RNA suppression. Int J STD AIDS. 2022;33(8):777-83.
- 475 20. Hermans LE, Ummnakwe CN, Lalla-Edward ST, Hebel SK, Tempelman HA, Nijhuis M,
476 et al. Point-Of-Care Tenofovir urine Testing for the Prediction of Treatment Failure and Drug
477 Resistance During Initial Treatment for HIV-1 Infection. Clin Infect Dis. 2022.
- 478 21. van Zyl G, Jennings L, Kellermann T, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Urine
479 tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.
480 AIDS. 2022;36(14):2057-62.
- 481 22. McCluskey SM, Govender K, Adamson J, Gandhi M, Spinelli MA, Moosa MY, et al.
482 Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with
483 virologic failure. AIDS. 2023;10.1097/QAD.0000000000003520.
- 484 23. Jennings L, Kellermann T, Spinelli M, Nkantsu Z, Cogill D, van Schalkwyk M, et al. Drug
485 Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir,
486 Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS Res Hum Retroviruses.
487 2022;38(6):455-62.

488

489

490 **TABLE 1: BASELINE DEMOGRAPHICS OF STUDY POPULATION, N = 124**

Variable	Levels	Total
Age, years	Median (IQR)	39.0 (34.0 to 45.0)
Gender	Female	68 (54.8)
	Male	56 (45.2)
Ethnicity	Black African	121 (97.6)
	Coloured	1 (0.8)
	Other	2 (1.6)
Time since ART initiation, years	Median (IQR)	4.1 (1.5 to 6.1)
Current ART regimen	TDF / FTC / EFV	74 (59.7)
	TDF / 3TC / DTG	50 (40.3)
Time on current regimen, years	Median (IQR)	1.6 (0.7 to 5.0)
ART side effects	No	120 (96.8)
	Yes	4 (3.2)
Enrolment CD4 count category, cells/ μ L	<200	21 (16.9)
	200-349	25 (20.2)
	350-499	29 (23.4)
	\geq 500	49 (39.5)
Last time participant missed a dose of ART	<2 weeks	30 (24.2)
	2-4 weeks	16 (12.9)
	1-3 months	16 (12.9)
	>3 months	8 (6.5)
	Never	54 (43.5)
Number of ART doses missed in past 4 days	0	95 (76.6)
	1	14 (11.3)
	2	9 (7.3)
	3	2 (1.6)
	4	4 (3.2)
POC urine tenofovir test	Not Present	24 (19.4)
	Present	100 (80.6)
Urine tenofovir concentration, ng/mL	Median (IQR)	20000.0 (7280.0 to 33625.0)
Enrolment viral load, copies/mL	<50	57 (46.0)
	50-999	23 (18.5)
	\geq 1000	44 (35.5)
Any HIV drug resistance against current regimen?	No	19 (15.3)
	Yes	24 (19.4)
	Unsuccessful	1 (0.8)
	Viral load <1000 copies/mL	80 (64.5)

491

492

493 **TABLE 2: ANALYTIC PERFORMANCE OF THE POINT-OF-CARE TENOFOVIR TEST TO**
 494 **DETECT URINE TENOFOVIR AT THE MANUFACTURER THRESHOLD OF 1500NG/ML**

		LCSM urine TFV (ng/mL)		
		<1500	≥1500	Total
POC TFV	TFV not detected	20	4	24
	TFV detected	1	99	100
	<i>Total</i>	21	103	124
Sensitivity		96.1% (90.0-98.8), p<0.001		
Specificity		95.2% (75.3-100.0), p<0.001		
PPV		99.0% (93.9-100.0), p<0.001		
NPV		83.3% (63.4-93.8), p=0.002		


495

496 **TABLE 3: ASSOCIATION OF POINT-OF-CARE URINE TFV RESULTS WITH VIRAEMIA ,**
 497 **AND HIV DRUG RESISTANCE**

		Viral load (copies/mL)					
		EFV only			DTG only		
		<1000	≥1000	Total	<1000	≥1000	Total
POC TFV	TFV not detected	3	8	11	2	11	13
	TFV detected	44	19	63	31	6	37
	<i>Total</i>	47	27	74	33	17	50
% with undetectable TFV, of those with viraemia		29.6 (13.8-50.2), p=0.052			64.7 (41.1-82.7), p=0.332*		
% with detectable TFV, of those suppressed		93.6 (82.0-98.4), p<0.001			93.9 (79.2-99.2), p<0.001†		
% with viraemia, of those with undetectable TFV		72.7 (42.8-90.5), p=0.227			84.6 (56.3-96.6), p=0.022‡		
% suppressed, of those with detectable TFV		69.8 (57.5-79.8), p=0.002			83.8 (68.4-92.6), p<0.001§		
		Presence of HIV drug resistance					
		No HIV DR	HIV DR	Total	No HIV DR	HIV DR	Total
POC TFV	TFV not detected	1	7	8	10	0	10
	TFV detected	3	16	19	5	1	6
	<i>Total</i>	4	23	27	15	1	16
% with detectable TFV, of those with HIV DR		69.6 (48.9-84.4), p=0.093			100 (17.0-100.0), p=1.000		
% with undetectable TFV, of those without HIV DR		25.0 (4.0-71.0), p=0.625			66.7 (41.5-84.8), p=0.302		
% with HIV DR, of those with detectable TFV		84.2 (61.4-95.1), p=0.004			16.7 (1.6-58.4), p=0.219		
% without HIVDR, of those with undetectable TFV		12.5 (0.5-49.5), p=0.070			100.0 (67.4-100.0), p=0.002		

498 *p for EFV vs DTG = 0.031, †p for EFV vs DTG = 1.00, ‡p for EFV vs DTG = 1.00, §p for EFV vs DTG = 0.639,
499 -M184V mutation

Figure 1: Flow diagram of POWER study participants



EAC = enhanced adherence counselling

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.12.23288474>; this version posted April 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#) .